Skip header and navigation

14 records – page 1 of 2.

Document Type
Rapid Review
Review Code
EPM051201 RR
Question Submitted
May 12, 2020
Date Completed
May 12, 2020
Status
3. Completed
Research Team
Epidemiology & Modelling
-oup-com.shal.idm.oclc.org/cid/article/doi/10.1093/cid/ciaa344/5812996 plasma samples for serology
Document Type
Rapid Review
Review Code
EPM051201 RR
Question Submitted
May 12, 2020
Date Completed
May 12, 2020
Status
3. Completed
Research Team
Epidemiology & Modelling
Key Findings
·      A wide range of tests are available for detection of viral RNA as well as serological and immunoassays for antibodies developed due to exposure to SARS CoV-2 in infected persons. Despite the emerging research, information about clinical validity of tests is limited. ·      Multiple factors affect test performance including the nature of the specific test, type of specimen and its quality, severity and duration of illness at the time of testing. These individual variations hamper assessment of diagnostic accuracy and suggest that a combination of tests on multiple types of specimens at serial time points might be needed to confirm a COVID 19 diagnosis. ·      Point of care tests are desirable and needed to scale up testing in low resource settings; however, tests are of variable quality and more research is needed before they can be relied on for clinical decision making.
Notes
No search conducted by SHA librarians. Search Alerts set up.
Category
Diagnostics
Subject
Antigens
Testing
Serology
Polymerase Chain Reaction
Priority Level
Level 4 completed within 1 week
Cite As
Williams-Roberts, H; Waldener, C. What is the accuracy of diagnostic tests for COVID-19 detection? 2020 May 12; Document no.: EPM051201 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. (CEST rapid review report)
Similar Reviews
PH042401 RR
LAB041401 RR
Related Documents
Documents

EPM051201 RR

Download File
Less detail
Document Type
Evidence Search Report
Review Code
LAB041402-01 ESR
Question Submitted
April 14, 2020
Date Completed
April 14, 2020
Status
3. Completed
Research Team
Laboratory
Document Type
Evidence Search Report
Review Code
LAB041402-01 ESR
Question Submitted
April 14, 2020
Date Completed
April 14, 2020
Status
3. Completed
Research Team
Laboratory
Category
Clinical Presentation
Subject
Antibodies
Natural History
Serology
Population
All
Priority Level
Level 2 completed within 8 hours
Cite As
Duncan, V. At what time in the disease timeline of COVID-19 do antibodies develop? 2020 Apr 14; Document no.: LAB041402-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 42 p. (CEST evidence search report)
Related Documents
Documents
Less detail
Document Type
Rapid Review
Review Code
LAB041402 RR
Question Submitted
April 14, 2020
Date Completed
April 15, 2020
Status
3. Completed
Research Team
Laboratory
?show=grade Background The EOC has requested more information regarding whether serology have
Document Type
Rapid Review
Review Code
LAB041402 RR
Question Submitted
April 14, 2020
Date Completed
April 15, 2020
Status
3. Completed
Research Team
Laboratory
Key Findings
The majority of patients (>50%) appear to seroconvert between 8-14 days following the onset of symptoms.
Nearly all patients (>80%) seroconvert >15 days following the onset of symptoms.
The IgM response is detected earlier (median 12 days) than the IgG response (median 14 days).
Seroconversion appears to follow clinical recovery in most cases.
Category
Clinical Presentation
Subject
Antibodies
Natural History
Serology
Population
All
Priority Level
Level 2 completed within 8 hours
Cite As
Vanstone, J; Reeder, B; Duncan, V. At what time in the disease timeline of COVID-19 do antibodies develop? 2020 Apr 15; Document no.: LAB041402 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 4 p. (CEST rapid review report)
Related Documents
Documents
Less detail
Document Type
Evidence Search Report
Review Code
LAB041501-01 ESR
Question Submitted
April 15, 2020
Date Completed
April 15, 2020
Status
3. Completed
Research Team
Laboratory
al. Serology characteristics of SARS-CoV-2 infection since the exposure and post symptoms onset
Document Type
Evidence Search Report
Review Code
LAB041501-01 ESR
Question Submitted
April 15, 2020
Date Completed
April 15, 2020
Status
3. Completed
Research Team
Laboratory
Category
Clinical Presentation
Subject
Antibodies
Natural History
Serology
Priority Level
Level 2 completed within 8 hours
Cite As
Howell-Spooner, B. How well does the presence and level of antibodies predict the clinical course of disease? 2020 Apr 15; Document no.: LAB041501-01 ESR In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 22 p. (CEST evidence search report)
Related Documents
Documents
Less detail
Document Type
Rapid Review
Review Code
LAB041501 RR
Question Submitted
April 15, 2020
Date Completed
April 17, 2020
Status
3. Completed
Research Team
Laboratory
T, Zheng S, et al. Serology characteristics of SARS-CoV-2 infection since the exposure and post
Document Type
Rapid Review
Review Code
LAB041501 RR
Question Submitted
April 15, 2020
Date Completed
April 17, 2020
Status
3. Completed
Research Team
Laboratory
Key Findings
Seroconversion occurs in majority of COVID-19 patients from the second week following symptomonseton.
Between 7.8 -43.6% of suspect cases and 4.7% of asymptomatic individuals with negative nucleic acid test (rt-PCR) test positive for antibodies against SARS-CoV-2.
An increase in antibody titrescorrelates with a neutralizing antibody response and positive recovery of COVID-19 patients with mild to moderate symptoms.
Although higher antibody titreand more robust antibody response are observed in severe and critically ill patients, those antibodies may not effectively clear virus and higher antibody levels may be associated with a worse clinical progress.
Category
Clinical Presentation
Subject
Antibodies
Natural History
Serology
Priority Level
Level 2 completed within 8 hours
Cite As
Wang, H; Reeder, B; Howell-Spooner, B. How well does the presence and level of antibodies predict the clinical course of disease? 2020 Apr 17; Document no.: LAB041501 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 5 p. (CEST rapid review report)
Related Documents
Documents
Less detail
Document Type
Evidence Search Report
Review Code
LAB041401-01 ESR
Question Submitted
April 14, 2020
Date Completed
April 14, 2020
Status
3. Completed
Research Team
Laboratory
diagnostic kits. Here we report the development and validation of a COVID-19/SARS-CoV-2 S1 serology ELISA
Document Type
Evidence Search Report
Review Code
LAB041401-01 ESR
Question Submitted
April 14, 2020
Date Completed
April 14, 2020
Status
3. Completed
Research Team
Laboratory
Category
Clinical Presentation
Subject
Testing
Antibodies
Serology
Priority Level
Level 2 completed within 8 hours
Cite As
Howell-Spooner, B. How well does the presence and level of antibodies predict the presence or absence of the disease? 2020 Apr 14; Document no.: LAB041401-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 20 p. (CEST evidence search report)
Related Documents
Documents
Less detail
Document Type
Rapid Review
Review Code
LAB041401 RR
Question Submitted
April 14, 2020
Date Completed
April 15, 2020
Status
3. Completed
Research Team
Laboratory
studies with some limitations. Background SARS-CoV-2 serology assays, such as enzyme-linked
Document Type
Rapid Review
Review Code
LAB041401 RR
Question Submitted
April 14, 2020
Date Completed
April 15, 2020
Status
3. Completed
Research Team
Laboratory
Key Findings
Moderate to strong grade evidence show the overall sensitivityrangeof IgM, IgG, and combined IgM/IgG are 48.1% to 94.1%, 64.7% to 100%, 83% to 100%, respectively.
IgM/IgG combined assay, with the posterior probability of 99.15%, has greater accuracyand sensitivity than a single IgM or IgG test.
The sensitivity of antibody tests is extremely low (~ 11.1%) in the first week following the onsetof symptoms but increasesrapidlyduring the second week.
IgG and IgM titers in patients with severe disease arehigher than those in the non-severe patients.
Antibody testsmay detect the presence of COVID-19 in asymptomatic individuals with negative rt-PCRresults.
Category
Clinical Presentation
Subject
Testing
Serology
Antibodies
Priority Level
Level 2 completed within 8 hours
Cite As
Wang, H; Reeder, B; Howell-Spooner, B. How well does the presence and level of antibodies predict the presence or absence of the disease? 2020 Apr 15; Document no.: LAB041401 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 9 p. (CEST rapid review report)
Similar Reviews
PH042401 RR
EPM051201 RR
Related Documents
Documents
Less detail
Document Type
Evidence Search Report
Review Code
LAB040803-01 ESR
Question Submitted
April 8, 2020
Date Completed
April 8, 2020
Status
3. Completed
Research Team
Laboratory
/2020.03.18.20038018 15. Lou B, Li T, Zheng S, et al. Serology characteristics of SARS-CoV-2 infection since
Document Type
Evidence Search Report
Review Code
LAB040803-01 ESR
Question Submitted
April 8, 2020
Date Completed
April 8, 2020
Status
3. Completed
Research Team
Laboratory
Category
Clinical Presentation
Subject
Testing
Serology
Immunity
Natural History
Population
All
Priority Level
Level 2 completed within 8 hours
Cite As
Duncan, V. Is the IgM or IgG immune response protective? 2020 Apr 8; Document no.: LAB040803-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 13 p. (CEST evidence search report)
Related Documents
Documents
Less detail
Document Type
Rapid Review
Review Code
LAB040803 RR
Question Submitted
April 8, 2020
Date Completed
April 11, 2020
Status
3. Completed
Research Team
Laboratory
S, et al. Serology characteristics of SARS-CoV-2 infection since the exposure and post symptoms
Document Type
Rapid Review
Review Code
LAB040803 RR
Question Submitted
April 8, 2020
Date Completed
April 11, 2020
Status
3. Completed
Research Team
Laboratory
Key Findings
Low grade evidence shows IgG and IgM antibody response correlates with neutralizingantibody titerand viral clearance, which is suggestive of protective humoral immunity inCOVID-19 patients with mild to moderate symptoms.
There is no available evidence with which to estimate the durability of this protective response. However, if the immune response to SARS-CoV-2 resembles that toward SARS-CoV, this protective humoral immunity may persist for several years.
Higher IgG antibody titersand a robustresponse were noted in severe to criticallyill patients and were associated with lower viral clearance and a worse clinical prognosis.
Low grade evidence suggests that convalescent plasma treatment may improve the clinical status of critically ill COVID-19 patients(one case series with only five patients enrolled).
Category
Clinical Presentation
Subject
Testing
Serology
Immunity
Natural History
Population
All
Priority Level
Level 2 completed within 8 hours
Cite As
Wang, H; Reeder, B; Duncan, V; Is the IgM or IgG immune response protective? 2020 Apr 11; Document no.: LAB040803 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 6 p. (CEST rapid review report)
Related Documents
Documents
Less detail
Document Type
Table
Review Code
EPM072101 RR Table
Question Submitted
July 21, 2020
Date Completed
July 21, 2020
Status
3. Completed
Research Team
Epidemiology & Modelling
Document Type
Table
Review Code
EPM072101 RR Table
Question Submitted
July 21, 2020
Date Completed
July 21, 2020
Status
3. Completed
Research Team
Epidemiology & Modelling
Category
Diagnostics
Subject
Antigens
Testing
Serology
Polymerase Chain Reaction
Priority Level
Level 2 completed within 8 hours
Cite As
Williams-Roberts, H; Waldner, C; Dalidowicz, M; Howell-Spooner, B. What is the accuracy of diagnostic tests for the detection of SARS-CoV-2? 2020 Jul 23; Document no.: EPM072101 RR Table. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. (CEST table)
Related Documents
Documents

EPM072101 RR Table

Download File
Less detail

14 records – page 1 of 2.